Loopbaan van Wilfried van Langenaeker
Eerdere bekende functies van Wilfried van Langenaeker
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Silicos SA
 Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Oprichter | 28-08-2009 | 11-05-2012 |
| President | 01-01-2005 | 11-05-2012 | |
| The University of North Carolina at Charlotte | Corporate Officer/Principal | - | - |
Opleiding van Wilfried van Langenaeker
| Université Libre de Bruxelles | Undergraduate Degree |
Statistieken
Internationaal
| België | 3 |
| Verenigde Staten | 2 |
Operationeel
| Founder | 1 |
| President | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
